Table 2 Treatment-related adverse events occurring in at least 10% of patients in either group
Preferred term | Camrelizumab + fuzuloparib + apatinib 375 mg (n = 3) | Camrelizumab + fuzuloparib + apatinib 500 mg (n = 29) | ||
|---|---|---|---|---|
All grade | Grade ≥ 3 | All grade | Grade ≥ 3 | |
White blood cell count decreased | 2 (66.7) | 0 | 17 (58.6) | 6 (20.7) |
Neutrophil count decreased | 1 (33.3) | 0 | 15 (51.7) | 3 (10.3) |
Platelet count decreased | 0 | 0 | 13 (44.8) | 2 (6.9) |
Aspartate aminotransferase increased | 2 (66.7) | 0 | 12 (41.4) | 3 (10.3) |
Hypertension | 0 | 0 | 12 (41.4) | 4 (13.8) |
Alanine aminotransferase increased | 2 (66.7) | 0 | 10 (34.5) | 1 (3.4) |
Blood bilirubin increased | 0 | 0 | 9 (31.0) | 0 |
Nausea | 1 (33.3) | 0 | 8 (27.6) | 0 |
Asthenia | 1 (33.3) | 0 | 8 (27.6) | 0 |
Hypothyroidism | 1 (33.3) | 0 | 7 (24.1) | 0 |
Anemia | 0 | 0 | 7 (24.1) | 2 (6.9) |
Blood pressure increased | 1 (33.3) | 0 | 6 (20.7) | 1 (3.4) |
Vomiting | 2 (66.7) | 1 (33.3) | 5 (17.2) | 0 |
Diarrhea | 1 (33.3) | 0 | 4 (13.8) | 0 |
Blood creatinine increased | 0 | 0 | 4 (13.8) | 0 |
Blood lactate dehydrogenase increased | 0 | 0 | 4 (13.8) | 0 |
Sinus tachycardia | 0 | 0 | 4 (13.8) | 0 |
Gamma-glutamyltransferase increased | 1 (33.3) | 0 | 3 (10.3) | 1 (3.4) |
Blood thyroid stimulating hormone increased | 0 | 0 | 3 (10.3) | 0 |
Blood creatine phosphokinase increased | 0 | 0 | 3 (10.3) | 0 |
Tri-iodothyronine free decreased | 0 | 0 | 3 (10.3) | 0 |
Decreased appetite | 1 (33.3) | 0 | 3 (10.3) | 0 |
Rash | 0 | 0 | 3 (10.3) | 0 |
Proteinuria | 2 (66.7) | 0 | 1 (3.4) | 0 |
Hypersensitivity | 1 (33.3) | 0 | 1 (3.4) | 0 |
Tri-iodothyronine decreased | 1 (33.3) | 0 | 1 (3.4) | 0 |
Infusion related reaction | 1 (33.3) | 0 | 0 | 0 |
Nasopharyngitis | 1 (33.3) | 0 | 0 | 0 |
Eczema | 1 (33.3) | 0 | 0 | 0 |